¡Ya estamos en ! Descubre más
19.98 USD
-0.71
3.43%
Al cierre Actualizado 16 oct, 4:00 p.m. EDT
1 día
-3.43%
5 días
2.3%
1 mes
-4.13%
3 meses
26.3%
6 meses
29.82%
En lo que va del año
113.69%
1 año
119.8%
5 años
-51.28%
10 años
-55.33%
 

Acerca de: Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.

Empleados: 235

Noticias

Positivo
Neutral
Negativo
Sentimiento 3 meses
Positivo 90%
Neutral 10%
Negativo 0%
Positivo
Zacks Investment Research
hace 21 días
Is Anika Therapeutics (ANIK) Outperforming Other Medical Stocks This Year?
Here is how Anika Therapeutics (ANIK) and Concentra Group (CON) have performed compared to their sector so far this year.
Is Anika Therapeutics (ANIK) Outperforming Other Medical Stocks This Year?
Positivo
Zacks Investment Research
el mes pasado
Best Momentum Stocks to Buy for August 26th
BTSG, ANIK and OPHC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 26th, 2026.
Best Momentum Stocks to Buy for August 26th
Positivo
Zacks Investment Research
el mes pasado
Anika (ANIK) Is a Great Choice for 'Trend' Investors, Here's Why
Anika (ANIK) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Anika (ANIK) Is a Great Choice for 'Trend' Investors, Here's Why
Positivo
Zacks Investment Research
el mes pasado
Anika Stock Gains 43.4% in the Past 3 Months: Here Is Why?
ANIK's strong sales momentum and raised 2026 guidance bolster investor confidence, while Cingal and Hyalofast advance its pipeline.
Anika Stock Gains 43.4% in the Past 3 Months: Here Is Why?
Positivo
Zacks Investment Research
el mes pasado
5 Stocks With Recent Price Strength to Enhance Your Portfolio Returns
Five stocks, including EDRY, OPHC, FET, ANIK and NESR, show strong recent price gains and earnings growth as markets rally.
5 Stocks With Recent Price Strength to Enhance Your Portfolio Returns
Positivo
Zacks Investment Research
hace 2 meses
Anika Therapeutics (ANIK) Is Up 11.10% in One Week: What You Should Know
Does Anika Therapeutics (ANIK) have what it takes to be a top stock pick for momentum investors? Let's find out.
Anika Therapeutics (ANIK) Is Up 11.10% in One Week: What You Should Know
Positivo
Zacks Investment Research
hace 2 meses
5 Stocks With Recent Price Strength to Tap August Rally
Five stocks, including OPHC, EDRY, ENVA, ANIK and GEO, show strong recent price gains and earnings growth as markets rally.
5 Stocks With Recent Price Strength to Tap August Rally
Positivo
Zacks Investment Research
hace 2 meses
Anika (ANIK) is on the Move, Here's Why the Trend Could be Sustainable
Anika (ANIK) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Anika (ANIK) is on the Move, Here's Why the Trend Could be Sustainable
Neutral
Seeking Alpha
hace 2 meses
Anika Therapeutics, Inc. (ANIK) Q2 2026 Earnings Call Transcript
Anika Therapeutics, Inc. (ANIK) Q2 2026 Earnings Call Transcript
Anika Therapeutics, Inc. (ANIK) Q2 2026 Earnings Call Transcript
Positivo
MarketBeat
hace 2 meses
Anika Therapeutics Q2 Earnings Call Highlights
Anika Therapeutics NASDAQ: ANIK reported higher second-quarter revenue, expanded gross margin and its strongest adjusted EBITDA performance since 2020, as international commercial growth and manufacturing improvements supported profitability.
Anika Therapeutics Q2 Earnings Call Highlights
Gráficos de precios implementados con Lightweight Charts™